speb/financial-data huggingface dataset:
Financial ratios for FTS.TO — annual report dated 2021-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 40.44094488188976
Shares outstanding: 509132995
Market cap (USD): 20589819388.346455
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for FTS.TO — annual report dated 2022-12-31
Total revenue: 8119852941.17647
Gross profit: 5213970588.235293
Operating income: 2014705882.352941
Net income: 1113235294.117647
Capital expenditures: 2637500000
Operating cash flow: 2260294117.6470585
Depreciation & amortization: 1226470588.235294
Net tangible assets: 5160294117.6470585
Owner earnings: -297794117.64705896
Return on net tangible assets (%): -5.77087489313195
Capex to operating income (%): 130.91240875912408
Buffett classification: The Gruesome
Stock price: 34.79411764705882
P/E ratio: 15.912928218890356
Shares outstanding: 509132995
Book value: 16795588235.29412
P/B ratio: 1.0547313424130982
Market cap (USD): 17714833326.02941
Debt to equity: 1.271123369232116
Current ratio: 0.6451564152939399
Quick ratio: 0.5452622034154451
Effective tax rate (%): 16.028840820854132
Interest coverage ratio: 2.4863883847549912
COGS to revenue (%): 35.78737661867247
Free cash flow (dilution-adjusted): -581617647.0588235
Buyback yield (%): 0
Retained earnings: 2744852941.1764703
Inventory turnover: 5.978819969742815
Receivables turnover: 6.277998862990335
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 4.754055695324022
FCF margin (%): -7.1629086299012945
Rule of 40 score: -7.1629086299012945
Financial ratios for FTS.TO — annual report dated 2023-12-31
Total revenue: 8725000000
Gross profit: 5868181818.181818
Operating income: 2336363636.363636
Net income: 1295454545.4545455
Capital expenditures: 3019696969.6969695
Operating cash flow: 2685606060.6060605
Depreciation & amortization: 1343181818.181818
Net tangible assets: 5917424242.424242
Owner earnings: -381060606.060606
Return on net tangible assets (%): -6.439636410190756
Capex to operating income (%): 129.24773022049288
Buffett classification: The Gruesome
Stock price: 37.553030303030305
P/E ratio: 14.758902083128655
Shares outstanding: 509132995
Book value: 17675757575.757572
P/B ratio: 1.081678491434511
Market cap (USD): 19119486789.507576
Debt to equity: 1.2869878278758788
Current ratio: 0.6748826291079812
Quick ratio: 0.5799798792756539
Effective tax rate (%): 17.391304347826086
Interest coverage ratio: 2.3632183908045974
COGS to revenue (%): 32.74290179734305
Free cash flow (dilution-adjusted): -472727272.7272727
Buyback yield (%): 0
Retained earnings: 3115151515.151515
Inventory turnover: 6.662544169611308
Receivables turnover: 7.078672403196067
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 5.143772099539662
FCF margin (%): -5.418077624381349
Revenue growth (%): 7.452684958797438
Rule of 40 score: 2.0346073344160898
Financial ratios for FTS.TO — quarterly report dated 2024-09-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 42.73333333333333
Shares outstanding: 509132995
Market cap (USD): 21756949986.333332
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for FTS.TO — annual report dated 2024-12-31
Total revenue: 8047552447.552448
Gross profit: 5775524475.524476
Operating income: 2302097902.0979023
Net income: 1278321678.3216784
Capital expenditures: 3504895104.895105
Operating cash flow: 2714685314.6853147
Depreciation & amortization: 1347552447.5524476
Net tangible assets: 6318181818.181818
Owner earnings: -879020979.0209789
Return on net tangible assets (%): -13.912562257885996
Capex to operating income (%): 152.2478736330498
Buffett classification: The Gruesome
Stock price: 39.60139860139861
P/E ratio: 15.772539117532824
Shares outstanding: 509132995
Book value: 18079020979.020977
P/B ratio: 1.1152362010927168
Market cap (USD): 20162378676.118885
Debt to equity: 1.3036011294627319
Current ratio: 0.6288933068257123
Quick ratio: 0.5154075546719682
Effective tax rate (%): 15.915363385464582
Interest coverage ratio: 2.341394025604552
COGS to revenue (%): 28.232533889468197
Free cash flow (dilution-adjusted): -934265734.2657343
Buyback yield (%): 0
Retained earnings: 3161538461.5384617
Inventory turnover: 4.743065693430657
Receivables turnover: 6.895146794487718
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 4.88065233506301
FCF margin (%): -11.609315258950295
Revenue growth (%): -7.764441861863057
Rule of 40 score: -19.37375712081335
Financial ratios for FTS.TO — quarterly report dated 2024-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 39.60139860139861
Shares outstanding: 509132995
Market cap (USD): 20162378676.118885
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for FTS.TO — quarterly report dated 2025-03-31
Total revenue: 2334265734.265734
Gross profit: 1606993006.993007
Operating income: 666433566.4335665
Net income: 390209790.2097902
Capital expenditures: 1037062937.0629371
Operating cash flow: 848251748.2517483
Depreciation & amortization: 360139860.13986015
Net tangible assets: 6530769230.769231
Owner earnings: -286713286.71328676
Return on net tangible assets (%): -4.390191669343613
Capex to operating income (%): 155.61385099685205
Buffett classification: The Gruesome
Stock price: 43.88811188811189
P/E ratio: 14.315943891666667
Shares outstanding: 509132995
Book value: 18316783216.78322
P/B ratio: 1.219913212163555
Market cap (USD): 22344885850.48951
Debt to equity: 1.3135188790898331
Current ratio: 0.758785648574057
Quick ratio: 0.6336706531738729
Effective tax rate (%): 17.210682492581604
Interest coverage ratio: 2.575675675675676
COGS to revenue (%): 31.15638106650689
Free cash flow (dilution-adjusted): -230769230.76923078
Buyback yield (%): 0
Retained earnings: 3294405594.4055943
Inventory turnover: 1.5294117647058822
Receivables turnover: 1.7385416666666667
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 1.3755178037902516
FCF margin (%): -9.88615937687238
Rule of 40 score: -9.88615937687238
Financial ratios for FTS.TO — quarterly report dated 2025-06-30
Total revenue: 2054744525.547445
Gross profit: 1533576642.3357663
Operating income: 583941605.839416
Net income: 324087591.2408759
Capital expenditures: 1079562043.7956204
Operating cash flow: 586861313.8686131
Depreciation & amortization: 373722627.73722625
Net tangible assets: 6937956204.379561
Owner earnings: -381751824.81751823
Return on net tangible assets (%): -5.502367175170963
Capex to operating income (%): 184.875
Buffett classification: The Gruesome
Stock price: 45.86131386861313
P/E ratio: 32.688777378885995
Shares outstanding: 509132995
Book value: 18681751824.817513
P/B ratio: 1.2498564536942256
Market cap (USD): 23349508084.56204
Debt to equity: 1.321012737360319
Current ratio: 0.5787082116196041
Quick ratio: 0.46851671535215833
Effective tax rate (%): 17.16417910447761
Interest coverage ratio: 2.168021680216802
COGS to revenue (%): 25.364120781527532
Free cash flow (dilution-adjusted): -540145985.4014598
Buyback yield (%): 0
Retained earnings: 3718978102.1897807
Inventory turnover: 1.0515463917525774
Receivables turnover: 1.6423570595099182
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 1.2007144250829245
FCF margin (%): -26.287744227353464
Revenue growth (%): -11.974695280621733
Rule of 40 score: -38.262439507975195
Financial ratios for FTS.TO — quarterly report dated 2025-09-30
Total revenue: 2113669064.7482016
Gross profit: 1567625899.2805758
Operating income: 626618705.0359713
Net income: 341007194.24460435
Capital expenditures: 979856115.1079137
Operating cash flow: 738848920.8633094
Depreciation & amortization: 372661870.50359714
Net tangible assets: 7055395683.453238
Owner earnings: -266187050.35971224
Return on net tangible assets (%): -3.7728153359845007
Capex to operating income (%): 156.3719862227325
Buffett classification: The Gruesome
Stock price: 49.510791366906474
P/E ratio: 23.886542401131567
Shares outstanding: 509132995
Book value: 18887050359.712234
P/B ratio: 1.3346487150382809
Market cap (USD): 25207577493.453236
Debt to equity: 1.3110501656953488
Current ratio: 0.6636413142131058
Quick ratio: 0.5447449627881649
Effective tax rate (%): 18.134715025906733
Interest coverage ratio: 2.354054054054054
COGS to revenue (%): 25.833900612661676
Free cash flow (dilution-adjusted): -306474820.1438849
Buyback yield (%): 0
Retained earnings: 3737410071.942446
Inventory turnover: 1.1587786259541986
Receivables turnover: 1.81134401972873
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 1.2624286169811867
FCF margin (%): -14.499659632402995
Revenue growth (%): 2.8677306822393067
Rule of 40 score: -11.631928950163688
Financial ratios for FTS.TO — quarterly report dated 2025-12-31
Total revenue: 2247445255.4744525
Gross profit: 1621167883.2116787
Operating income: 633576642.3357663
Net income: 354014598.54014593
Capital expenditures: 1181021897.8102188
Operating cash flow: 743065693.4306569
Depreciation & amortization: 373722627.73722625
Net tangible assets: 6978102189.781021
Owner earnings: -453284671.5328467
Return on net tangible assets (%): -6.49581589958159
Capex to operating income (%): 186.40552995391707
Buffett classification: The Gruesome
Stock price: 51.22627737226277
P/E ratio: 18.506090386083287
Shares outstanding: 509132995
Book value: 18882481751.824814
P/B ratio: 1.3812267033553678
Market cap (USD): 26080988021.240875
Debt to equity: 1.3403301248598711
Current ratio: 0.5064554771729004
Quick ratio: 0.4200718754159457
Effective tax rate (%): 14.15929203539823
Interest coverage ratio: 2.35230352303523
COGS to revenue (%): 27.86619032153296
Free cash flow (dilution-adjusted): -493430656.9343065
Buyback yield (%): 0
Retained earnings: 3627007299.270073
Inventory turnover: 1.3220338983050846
Receivables turnover: 2.0622906898861353
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 1.289421691400389
FCF margin (%): -21.955180253329
Revenue growth (%): 6.329098199778377
Rule of 40 score: -15.626082053550624
Financial ratios for FTS.TO — annual report dated 2025-12-31
Total revenue: 8883211678.832115
Gross profit: 6422627737.226276
Operating income: 2548905109.489051
Net income: 1431386861.3138685
Capital expenditures: 4337226277.372262
Operating cash flow: 2964963503.649635
Depreciation & amortization: 1501459854.0145984
Net tangible assets: 6978102189.781021
Owner earnings: -1404379562.043795
Return on net tangible assets (%): -20.125523012552296
Capex to operating income (%): 170.16036655211911
Buffett classification: The Gruesome
Stock price: 51.22627737226277
P/E ratio: 18.22078204441611
Shares outstanding: 509132995
Book value: 18882481751.824814
P/B ratio: 1.3812267033553678
Market cap (USD): 26080988021.240875
Debt to equity: 1.3403301248598711
Current ratio: 0.5064554771729004
Quick ratio: 0.4200718754159457
Effective tax rate (%): 16.69498725573492
Interest coverage ratio: 2.3626522327469552
COGS to revenue (%): 27.69926047658176
Free cash flow (dilution-adjusted): -1585401459.8540144
Buyback yield (%): 0
Retained earnings: 3627007299.270073
Inventory turnover: 5.194144838212635
Receivables turnover: 8.151373074346951
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 5.1873969428227635
FCF margin (%): -17.847165160230073
Revenue growth (%): 10.384017211765064
Rule of 40 score: -7.463147948465009
Financial ratios for FWTC.V — annual report dated 2022-03-31
Total revenue: 4995.2
Operating income: -3330412
Net income: -3342940.8
Capital expenditures: 309881.6
Operating cash flow: -2124008
Depreciation & amortization: 212201.6
Net tangible assets: 2811038.4
Owner earnings: -3440620.8
Return on net tangible assets (%): -122.39679116443234
Buffett classification: The Gruesome
Stock price: 1.08
Shares outstanding: 49174592
Book value: 2811038.4
P/B ratio: 18.892861570300855
Market cap (USD): 53108559.36000001
Debt to equity: 0.09037343637852831
Current ratio: 7.826935635082275
Quick ratio: 7.826935635082275
Interest coverage ratio: -37.2003342030954
COGS to revenue (%): 0
R&D to revenue (%): 14679.356181934656
SG&A to revenue (%): 34205.317104420246
Free cash flow (dilution-adjusted): -2461632
Buyback yield (%): 0
Retained earnings: -8303838.4
Receivables turnover: 0.02879582359099231
Capitalized R&D asset: 733263.2
ROCI (R&D-adjusted, %): -70.90042363718506
FCF margin (%): -49279.94875080077
Rule of 40 score: -49279.94875080077
Financial ratios for FWTC.V — annual report dated 2023-03-31
Total revenue: 29426.666666666664
Operating income: -1672045.9259259258
Net income: -1693722.962962963
Capital expenditures: 433765.9259259259
Operating cash flow: -1080983.7037037036
Depreciation & amortization: 196559.25925925924
Net tangible assets: 1060133.3333333333
Owner earnings: -1930929.6296296294
Return on net tangible assets (%): -182.1402618818038
Buffett classification: The Gruesome
Stock price: 0.48148148148148145
Shares outstanding: 49174592
Book value: 1060133.3333333333
P/B ratio: 22.333658100308835
Market cap (USD): 23676655.407407407
Debt to equity: 0.23530862644810577
Current ratio: 1.6072065435950524
Quick ratio: 1.6072065435950524
Interest coverage ratio: -84.05995605705135
COGS to revenue (%): 0
R&D to revenue (%): 2551.3769319840912
SG&A to revenue (%): 3537.7561294869856
Free cash flow (dilution-adjusted): -1563497.7777777778
Buyback yield (%): 0
Retained earnings: -9382462.222222222
Receivables turnover: 0.5160963442201263
Capitalized R&D asset: 1242071.5291851852
ROCI (R&D-adjusted, %): -61.50380267434083
FCF margin (%): -5313.2004228968435
Revenue growth (%): 489.0988682468502
Rule of 40 score: -4824.101554649993
Financial ratios for FWTC.V — annual report dated 2024-03-31
Total revenue: 52634.07407407407
Operating income: -1573094.074074074
Net income: -1627046.6666666665
Capital expenditures: 288146.6666666666
Operating cash flow: -738527.4074074074
Depreciation & amortization: 28088.888888888887
Net tangible assets: -181182.22222222222
Owner earnings: -1887104.444444444
Buffett classification: The Gruesome
Stock price: 0.1102941176470588
Shares outstanding: 49174592
Book value: -181182.22222222225
Market cap (USD): 5423668.235294117
Debt to equity: -1.798884691491275
Current ratio: 0.15777736645826476
Quick ratio: 0.15777736645826476
Interest coverage ratio: -25.080330676114556
COGS to revenue (%): 0
R&D to revenue (%): 466.60943481197927
SG&A to revenue (%): 2715.1275050664262
Free cash flow (dilution-adjusted): -1056743.7037037036
Buyback yield (%): 0
Retained earnings: -11009508.888888888
Receivables turnover: 4.819970153303487
Capitalized R&D asset: 990598.4856296297
ROCI (R&D-adjusted, %): -175.578303473782
FCF margin (%): -2007.7178563386624
Revenue growth (%): 78.8652268036047
Rule of 40 score: -1928.8526295350578
Financial ratios for FYB.DE — annual report dated 2021-12-31
Capital expenditures: 0
Depreciation & amortization: 1071590.9090909092
Buffett classification: The Gruesome
Stock price: 67.04545454545455
Shares outstanding: 17672927
Market cap (USD): 1184889423.8636365
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for FYB.DE — annual report dated 2022-12-31
Total revenue: 45209574.46808511
Gross profit: 12841489.36170213
Operating income: -18860638.297872342
Net income: 38289361.702127665
Capital expenditures: 586170.2127659575
Operating cash flow: -20082978.723404255
Depreciation & amortization: 1980851.0638297873
Net tangible assets: -187651063.82978725
Owner earnings: 39684042.5531915
Return on net tangible assets (%): -21.147784480021773
Buffett classification: The Gruesome
Stock price: 92.02127659574468
P/E ratio: 42.47355483162925
Shares outstanding: 17672927
Book value: 379340425.5319149
P/B ratio: 4.287139451175052
Market cap (USD): 1626285303.7234042
Debt to equity: 0.08219473890851983
Current ratio: 0.6020091973079125
Quick ratio: 0.590739534608325
Effective tax rate (%): 1.6504536014865008
Interest coverage ratio: -141.83200000000002
COGS to revenue (%): 71.59564204532084
R&D to revenue (%): 39.79575028825565
SG&A to revenue (%): 30.326846600936534
Free cash flow (dilution-adjusted): -49119148.93617021
Buyback yield (%): 0
Retained earnings: -2093617.0212765958
Inventory turnover: 53.28546409807356
Receivables turnover: 2.9689115551208607
Capitalized R&D asset: 17991489.36170213
ROCI (R&D-adjusted, %): -0.7871694989808223
FCF margin (%): -108.64766924724097
Rule of 40 score: -108.64766924724097
Financial ratios for FYB.DE — annual report dated 2023-12-31
Total revenue: 86328888.88888888
Gross profit: 25894444.444444444
Operating income: -410000
Net income: 84216666.66666667
Capital expenditures: 1143333.3333333333
Operating cash flow: -10942222.222222222
Depreciation & amortization: 2096666.6666666665
Net tangible assets: -55761111.11111111
Owner earnings: 85170000.00000001
Return on net tangible assets (%): -152.7408588223573
Buffett classification: The Gruesome
Stock price: 62.666666666666664
P/E ratio: 13.150644274688304
Shares outstanding: 17672927
Book value: 558612222.2222221
P/B ratio: 1.9825979118887882
Market cap (USD): 1107503425.3333333
Debt to equity: 0.058649311488191976
Current ratio: 0.9688482959628314
Quick ratio: 0.9621100626208408
Effective tax rate (%): 4.1418995826482865
Interest coverage ratio: -4.6125
COGS to revenue (%): 70.00489085667216
R&D to revenue (%): 11.792112850082374
SG&A to revenue (%): 18.17854200988468
Free cash flow (dilution-adjusted): -36297777.77777778
Buyback yield (%): 0
Retained earnings: 82030000
Inventory turnover: 116.46895074946467
Receivables turnover: 6.691009300723389
Capitalized R&D asset: 22234297.872340426
ROCI (R&D-adjusted, %): 0.04060951684697678
Rosenberg metric: 0.7255072006727634
FCF margin (%): -42.04592257001649
Revenue growth (%): 90.95266855438157
Rule of 40 score: 48.90674598436509
Financial ratios for FYB.DE — quarterly report dated 2024-12-31
Capital expenditures: 0
Net tangible assets: 18464583.333333336
Buffett classification: The Gruesome
Stock price: 55.3125
Shares outstanding: 17672927
Book value: 481086458.3333334
P/B ratio: 2.031929516524013
Market cap (USD): 977533774.6875
Debt to equity: 0.022936365821285585
Current ratio: 2.80367627533709
Quick ratio: 2.7959460655592596
Buyback yield (%): 0
Retained earnings: -54003125
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for FYB.DE — annual report dated 2024-12-31
Total revenue: 72577083.33333334
Gross profit: 15452083.333333334
Operating income: -24526041.666666668
Net income: -130908333.33333334
Capital expenditures: 1609375
Operating cash flow: -24188541.666666668
Depreciation & amortization: 144859375
Net tangible assets: 18464583.333333336
Owner earnings: 12341666.666666657
Buffett classification: The Gruesome
Stock price: 55.3125
Shares outstanding: 17672927
Book value: 481086458.3333334
P/B ratio: 2.031929516524013
Market cap (USD): 977533774.6875
Debt to equity: 0.022936365821285585
Current ratio: 2.80367627533709
Quick ratio: 2.7959460655592596
Interest coverage ratio: -21.62075298438935
COGS to revenue (%): 78.70941814737203
R&D to revenue (%): 23.686023480781923
SG&A to revenue (%): 30.695811924103676
Free cash flow (dilution-adjusted): -57120833.333333336
Buyback yield (%): 0
Retained earnings: -54003125
Inventory turnover: 209.31297709923663
Receivables turnover: 2.94069978474655
Capitalized R&D asset: 29948416.489361703
ROCI (R&D-adjusted, %): -2.812242437992488
Rosenberg metric: -1.0257722113075747
FCF margin (%): -78.70367712489593
Revenue growth (%): -15.929552357907722
Rule of 40 score: -94.63322948280366
Financial ratios for FYB.DE — quarterly report dated 2025-06-30
Capital expenditures: 0
Net tangible assets: -56248235.29411765
Buffett classification: The Gruesome
Stock price: 32.94117647058824
Shares outstanding: 17672927
Book value: 480392941.17647064
P/B ratio: 1.2118558728883708
Market cap (USD): 582167007.0588236
Debt to equity: 0.024994244907355252
Current ratio: 1.5405610125592533
Quick ratio: 1.5118995259737087
Buyback yield (%): 0
Retained earnings: -124747058.82352942
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for GRL.AX — annual report dated 2021-06-30
Operating income: -1169393.2330827068
Net income: -1062245.112781955
Capital expenditures: 20548.872180451126
Depreciation & amortization: 43731.57894736842
Net tangible assets: 11730693.984962406
Owner earnings: -1039062.4060150377
Return on net tangible assets (%): -8.857637982433207
Buffett classification: The Gruesome
Stock price: 0.11278195488721804
Shares outstanding: 848582148
Book value: 14724199.2481203
P/B ratio: 6.499827387628723
Market cap (USD): 95704753.53383458
Debt to equity: 0.01772750448918294
Current ratio: 35.26170337426811
Quick ratio: 35.26170337426811
Interest coverage ratio: -141.35172225756614
Free cash flow (dilution-adjusted): -2801288.7218045113
Buyback yield (%): 0.17351531651594443
Retained earnings: -1664772.932330827
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -7.717883562501368
Rule of 40 score: 0
Financial ratios for GRL.AX — annual report dated 2022-06-30
Operating income: -953306.2068965518
Net income: -883232.4137931034
Capital expenditures: 198814.4827586207
Depreciation & amortization: 59175.17241379311
Net tangible assets: 9875833.103448275
Owner earnings: -1022871.7241379309
Return on net tangible assets (%): -10.357320880410402
Buffett classification: The Gruesome
Stock price: 0.06206896551724138
Shares outstanding: 848582148
Book value: 10388234.48275862
P/B ratio: 5.070218252213711
Market cap (USD): 52670616.08275862
Debt to equity: 0.018858337084261108
Current ratio: 9.464975037117384
Quick ratio: 9.464975037117384
Interest coverage ratio: -98.9260717097259
Free cash flow (dilution-adjusted): -2342996.551724138
Buyback yield (%): 0.017748559932127053
Retained earnings: -2410231.0344827585
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -8.90716882963237
Rule of 40 score: 0
Financial ratios for GRL.AX — annual report dated 2023-06-30
Operating income: -2160543.046357616
Net income: -2210458.940397351
Capital expenditures: 43333.774834437085
Depreciation & amortization: 64490.72847682119
Net tangible assets: 5513886.092715232
Owner earnings: -2189301.9867549674
Return on net tangible assets (%): -39.70524508381489
Buffett classification: The Gruesome
Stock price: 0.033112582781456956
Shares outstanding: 848582148
Book value: 5513886.092715232
P/B ratio: 5.095996933930086
Market cap (USD): 28098746.622516558
Debt to equity: 0.028694921719612663
Current ratio: 5.0910076160250926
Quick ratio: 5.0910076160250926
Interest coverage ratio: -247.90425531914892
Free cash flow (dilution-adjusted): -2131558.2781456956
Buyback yield (%): 0.23343644509476533
Retained earnings: -7035739.735099338
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -37.865109855035456
Rule of 40 score: 0
Financial ratios for GRX.L — annual report dated 2021-06-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 0.0020833333333333333
Shares outstanding: 311972551
Market cap (USD): 649942.8145833333
Buyback yield (%): 0
Capitalized R&D asset: 192766.91729323307
Rule of 40 score: 0
Financial ratios for GRX.L — annual report dated 2022-06-30
Total revenue: 180374.4827586207
Operating income: -3112688.9655172415
Net income: -2522382.7586206896
Capital expenditures: 149808.9655172414
Net tangible assets: 8146493.793103448
Owner earnings: -2672191.724137931
Return on net tangible assets (%): -32.80174013512562
Buffett classification: The Gruesome
Stock price: 0.0013414634146341464
Shares outstanding: 311972551
Book value: 8146493.793103449
P/B ratio: 0.051371764855559506
Market cap (USD): 418499.7635365854
Debt to equity: 0.07230307500176086
Current ratio: 2.7044726320540815
Quick ratio: 2.7044726320540815
COGS to revenue (%): 0
R&D to revenue (%): 106.58859155091133
SG&A to revenue (%): 221.55783179056598
Free cash flow (dilution-adjusted): -3060186.896551724
Buyback yield (%): 0
Retained earnings: -53552661.37931035
Receivables turnover: 8.507123341139735
Capitalized R&D asset: 321412.4552761214
ROCI (R&D-adjusted, %): -33.74677334809083
FCF margin (%): -1696.574177095162
Rule of 40 score: -1696.574177095162
Financial ratios for GRX.L — annual report dated 2023-06-30
Total revenue: 207383.44370860927
Operating income: -2299291.390728477
Net income: -2334335.0993377483
Capital expenditures: 1490376.1589403974
Net tangible assets: 10411596.026490066
Owner earnings: -3824711.2582781455
Return on net tangible assets (%): -36.73511004986162
Buffett classification: The Gruesome
Stock price: 0.00721518987341772
Shares outstanding: 311972551
Book value: 10411596.026490066
P/B ratio: 0.21619559431930108
Market cap (USD): 2250941.1907594935
Debt to equity: 0.03704097125530563
Current ratio: 5.204564959457495
Quick ratio: 5.204564959457495
COGS to revenue (%): 0
R&D to revenue (%): 106.23026099396773
SG&A to revenue (%): 277.80641164429716
Free cash flow (dilution-adjusted): -3211417.218543046
Buyback yield (%): 0
Retained earnings: -53759076.1589404
Receivables turnover: 6.796358190815175
Capitalized R&D asset: 412730.3320787697
ROCI (R&D-adjusted, %): -20.431583033903706
FCF margin (%): -1548.540790486318
Revenue growth (%): 14.973825863236037
Rule of 40 score: -1533.566964623082
Financial ratios for GRX.L — annual report dated 2024-06-30
Total revenue: 300756
Operating income: -2759411.3333333335
Net income: -3034786
Capital expenditures: 1087898
Net tangible assets: 10098565.333333334
Owner earnings: -4122684
Return on net tangible assets (%): -40.82445242386905
Buffett classification: The Gruesome
Stock price: 0.005949367088607594
Shares outstanding: 311972551
Book value: 10099806.666666666
P/B ratio: 0.1837697778507002
Market cap (USD): 1856039.2274683542
Debt to equity: 0.019972659542657912
Current ratio: 4.135392854553293
Quick ratio: 4.135392854553293
COGS to revenue (%): 0
SG&A to revenue (%): 205.82576352037313
Free cash flow (dilution-adjusted): -3414642
Buyback yield (%): 0
Retained earnings: -57152256
Receivables turnover: 33.045268092587165
Capitalized R&D asset: 211049.00707924186
ROCI (R&D-adjusted, %): -27.600854132686447
FCF margin (%): -1135.352910665124
Revenue growth (%): 45.02411312186851
Rule of 40 score: -1090.3287975432554
Financial ratios for GRX.L — quarterly report dated 2024-12-31
Capital expenditures: 74534.16149068323
Net tangible assets: 8526662.111801242
Buffett classification: The Gruesome
Stock price: 0.00425
Shares outstanding: 311972551
Book value: 8524547.826086957
P/B ratio: 0.15553708757343243
Market cap (USD): 1325883.3417500001
Debt to equity: 0
Buyback yield (%): 0
Retained earnings: -54544139.75155279
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for GRX.L — annual report dated 2025-06-30
Total revenue: 160043.7908496732
Operating income: -2107124.836601307
Net income: -3931297.385620915
Capital expenditures: 514701.30718954245
Net tangible assets: 9364944.444444444
Owner earnings: -4445998.692810457
Return on net tangible assets (%): -47.47490729053873
Buffett classification: The Gruesome
Stock price: 0.004794520547945205
Shares outstanding: 311972551
Book value: 9361272.549019607
P/B ratio: 0.15978156797934828
Market cap (USD): 1495758.8061643834
Debt to equity: 0
Current ratio: 2.0187729253106363
Quick ratio: 2.0187729253106363
COGS to revenue (%): 0
SG&A to revenue (%): 335.07087520980775
Free cash flow (dilution-adjusted): -2839712.4183006533
Buyback yield (%): 0
Retained earnings: -59962920.91503268
Receivables turnover: 1.3250809008950508
Capitalized R&D asset: 72700.31125827815
ROCI (R&D-adjusted, %): -22.636249924453562
FCF margin (%): -1774.3346388039217
Revenue growth (%): -46.786168571974216
Rule of 40 score: -1821.120807375896
Financial ratios for GRX.L — quarterly report dated 2025-06-30
Capital expenditures: 0
Net tangible assets: 9364944.444444444
Buffett classification: The Gruesome
Stock price: 0.004794520547945205
Shares outstanding: 311972551
Book value: 9361272.549019607
P/B ratio: 0.15978156797934828
Market cap (USD): 1495758.8061643834
Debt to equity: 0
Current ratio: 2.0187729253106363
Quick ratio: 2.0187729253106363
Buyback yield (%): 0
Retained earnings: -59962920.91503268
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for GRX.L — quarterly report dated 2025-12-31
Capital expenditures: 321244.96644295304
Net tangible assets: 4652639.597315436
Buffett classification: The Gruesome
Stock price: 0.005675675675675676
Shares outstanding: 311972551
Book value: 4576759.060402684
P/B ratio: 0.38687966655456824
Market cap (USD): 1770655.0191891892
Debt to equity: 0.10703054577907553
Current ratio: 0.8924272047396739
Quick ratio: 0.8924272047396739
Free cash flow (dilution-adjusted): 463406.71140939597
Buyback yield (%): 0
Retained earnings: -67011461.74496644
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for IMNN — annual report dated 2021-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 105.65
Shares outstanding: 4202118
Market cap (USD): 443953766.70000005
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for IMNN — annual report dated 2022-12-31
Total revenue: 500000
Operating income: -24921565
Net income: -35898234
Capital expenditures: 267800
Operating cash flow: -23096895
Depreciation & amortization: 731629
Net tangible assets: 29327866
Owner earnings: -35434405
Return on net tangible assets (%): -120.82162745833604
Buffett classification: The Gruesome
Stock price: 17.61
Shares outstanding: 4202118
Book value: 29327866
P/B ratio: 2.5231736253841315
Market cap (USD): 73999297.98
Debt to equity: 0.21366945007181906
Current ratio: 3.664380842958143
Quick ratio: 3.664380842958143
Interest coverage ratio: -4.955947140944092
COGS to revenue (%): 0
R&D to revenue (%): 2346.7331999999997
SG&A to revenue (%): 2737.5798
Free cash flow (dilution-adjusted): -26037742
Buyback yield (%): 38.513878885314256
Retained earnings: -368667825
Receivables turnover: 3.878013216269041
Capitalized R&D asset: 11733666
ROCI (R&D-adjusted, %): -37.438566394404965
FCF margin (%): -5207.548400000001
Rule of 40 score: -5207.548400000001
Financial ratios for IMNN — annual report dated 2023-12-31
Total revenue: 0
Operating income: -21030430
Net income: -19514977
Capital expenditures: 451759
Operating cash flow: -19022148
Depreciation & amortization: 720005
Net tangible assets: 13387642
Owner earnings: -19246731
Return on net tangible assets (%): -143.7649064712068
Buffett classification: The Gruesome
Stock price: 8.87
Shares outstanding: 4202118
Book value: 13387642
P/B ratio: 2.784118865742003
Market cap (USD): 37272786.66
Debt to equity: 0.12135923562939613
Current ratio: 2.4679168311655557
Quick ratio: 2.4679168311655557
Interest coverage ratio: -106.71011771869291
Free cash flow (dilution-adjusted): -20232920
Buyback yield (%): 0
Retained earnings: -388182802
Capitalized R&D asset: 19149247.22
ROCI (R&D-adjusted, %): -51.717634002832845
Revenue growth (%): -100
Rule of 40 score: -100
Financial ratios for IMNN — quarterly report dated 2024-09-30
Capital expenditures: 2879
Buffett classification: The Gruesome
Stock price: 13.83
Shares outstanding: 4202118
Market cap (USD): 58115291.94
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for IMNN — annual report dated 2024-12-31
Total revenue: 0
Operating income: -19132446
Net income: -18620242
Capital expenditures: 29541
Operating cash flow: -18854970
Depreciation & amortization: 718116
Net tangible assets: 4244298
Owner earnings: -17931667
Return on net tangible assets (%): -422.48840679895704
Buffett classification: The Gruesome
Stock price: 12.39
Shares outstanding: 4202118
Book value: 4244298
P/B ratio: 12.266867694021485
Market cap (USD): 52064242.02
Debt to equity: 0.2684290782598206
Current ratio: 1.6733681129914748
Quick ratio: 1.6733681129914748
Free cash flow (dilution-adjusted): -19361767
Buyback yield (%): 0
Retained earnings: -406803044
Capitalized R&D asset: 23074273.75
ROCI (R&D-adjusted, %): -68.0102827753093
Rule of 40 score: 0
Financial ratios for IMNN — quarterly report dated 2024-12-31
Capital expenditures: 14907
Buffett classification: The Gruesome
Stock price: 12.39
Shares outstanding: 4202118
Market cap (USD): 52064242.02
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for IMNN — quarterly report dated 2025-03-31
Total revenue: 0
Operating income: -4145299
Net income: -4102495
Capital expenditures: 259652
Operating cash flow: -2847051
Depreciation & amortization: 197927
Net tangible assets: 452028
Owner earnings: -4164220
Return on net tangible assets (%): -921.2305432406841
Buffett classification: The Gruesome
Stock price: 13.7
Shares outstanding: 4202118
Book value: 452028
P/B ratio: 127.3571915899015
Market cap (USD): 57569016.599999994
Debt to equity: 2.2300587574221065
Current ratio: 0.8783949040234871
Quick ratio: 0.8783949040234871
Free cash flow (dilution-adjusted): -3311236
Buyback yield (%): 0
Retained earnings: -410905539
Capitalized R&D asset: 2165092
ROCI (R&D-adjusted, %): -83.64275334121085
Rule of 40 score: 0
Financial ratios for IMNN — quarterly report dated 2025-06-30
Total revenue: 0
Operating income: -2767864
Net income: -2740559
Capital expenditures: 17331
Operating cash flow: -2951389
Depreciation & amortization: 164674
Net tangible assets: 2659850
Owner earnings: -2593216
Return on net tangible assets (%): -97.49482113653025
Buffett classification: The Gruesome
Stock price: 10.43
Shares outstanding: 4202118
Book value: 2659850
P/B ratio: 16.47765503317856
Market cap (USD): 43828090.74
Debt to equity: 0.4486745493166908
Current ratio: 1.2960077197262438
Quick ratio: 1.2960077197262438
Free cash flow (dilution-adjusted): -3091361
Buyback yield (%): 0
Retained earnings: -413646098
Capitalized R&D asset: 2677565.64
ROCI (R&D-adjusted, %): -43.450371619540064
Rule of 40 score: 0
Financial ratios for IMNN — quarterly report dated 2025-09-30
Total revenue: 0
Operating income: -3475828
Net income: -3429124
Capital expenditures: 0
Operating cash flow: -4441083
Depreciation & amortization: 167034
Net tangible assets: 4081724
Owner earnings: -3262090
Return on net tangible assets (%): -79.91941640346089
Buffett classification: The Gruesome
Stock price: 5.13
Shares outstanding: 4202118
Book value: 4081724
P/B ratio: 5.281313812496876
Market cap (USD): 21556865.34
Debt to equity: 0.2700407964869746
Current ratio: 1.728879738307997
Quick ratio: 1.728879738307997
Free cash flow (dilution-adjusted): -4229804
Buyback yield (%): 0
Retained earnings: -417075222
Capitalized R&D asset: 3435790.54
ROCI (R&D-adjusted, %): -40.60904955726449
Rule of 40 score: 0
Financial ratios for IMNN — annual report dated 2025-12-31
Total revenue: 0
Operating income: -14650694
Net income: -14495028
Capital expenditures: 280572
Operating cash flow: -13896624
Depreciation & amortization: 698900
Net tangible assets: 7061876
Owner earnings: -14076700
Return on net tangible assets (%): -199.33371812249322
Buffett classification: The Gruesome
Stock price: 3.81
Shares outstanding: 4202118
Book value: 7061876
P/B ratio: 2.2671128153482165
Market cap (USD): 16010069.58
Debt to equity: 0.1428466033671506
Current ratio: 2.3192345564682433
Quick ratio: 2.3192345564682433
Free cash flow (dilution-adjusted): -14304570
Buyback yield (%): 0
Retained earnings: -421298072
Capitalized R&D asset: 19304041.400000002
ROCI (R&D-adjusted, %): -63.42969827278332
Rule of 40 score: 0
Financial ratios for IMNN — quarterly report dated 2025-12-31
Total revenue: 0
Operating income: -4261703
Net income: -4222850
Capital expenditures: 3589
Operating cash flow: -3657101
Depreciation & amortization: 169265
Net tangible assets: 7061876
Owner earnings: -4057174
Return on net tangible assets (%): -57.45178759864943
Buffett classification: The Gruesome
Stock price: 3.81
Shares outstanding: 4202118
Book value: 7061876
P/B ratio: 2.2671128153482165
Market cap (USD): 16010069.58
Debt to equity: 0.1428466033671506
Current ratio: 2.3192345564682433
Quick ratio: 2.3192345564682433
Free cash flow (dilution-adjusted): -3672169
Buyback yield (%): 0
Retained earnings: -421298072
Capitalized R&D asset: 4166793.9899999998
ROCI (R&D-adjusted, %): -30.801671206095488
Rule of 40 score: 0
Financial ratios for INSECTICID.NS — annual report dated 2022-03-31
Total revenue: 197579084.79493603
Gross profit: 49989977.58143215
Operating income: 19256758.538836874
Net income: 14166978.768297508
Capital expenditures: 8823368.060134511
Operating cash flow: 17783041.01279177
Depreciation & amortization: 3474759.330080443
Net tangible assets: 113179862.85111433
Owner earnings: 8818370.038243439
Return on net tangible assets (%): 7.791465562954264
Capex to operating income (%): 45.81959130006026
Buffett classification: The Good
Stock price: 5.290122642753527
P/E ratio: 10.8654871928879
Shares outstanding: 29097837
Book value: 114679045.23275748
P/B ratio: 1.3422777112978765
Market cap (USD): 153931126.36885136
Debt to equity: 0.06203875939040344
Current ratio: 1.9747153400588158
Quick ratio: 0.7336037075161569
Effective tax rate (%): 24.010432029471122
Interest coverage ratio: 29.344479723483783
COGS to revenue (%): 74.69875030886195
R&D to revenue (%): 0.5108920306743463
SG&A to revenue (%): 1.1951004984374356
Free cash flow (dilution-adjusted): 8910681.78821047
Buyback yield (%): 5.071184965522338
Retained earnings: 101600171.43610708
Inventory turnover: 1.775825491943978
Receivables turnover: 5.185802750523256
Capitalized R&D asset: 1009415.7984966373
ROCI (R&D-adjusted, %): 16.86568195779949
FCF margin (%): 4.509931705301052
Rule of 40 score: 4.509931705301052
Financial ratios for INSECTICID.NS — annual report dated 2023-03-31
Total revenue: 218916175.39585873
Gross profit: 48645395.858708896
Operating income: 13028172.959805116
Net income: 7699293.544457979
Capital expenditures: 10563410.475030452
Operating cash flow: -1295066.9914738126
Depreciation & amortization: 3179269.1839220463
Net tangible assets: 110320207.06455542
Owner earnings: 315152.2533495724
Return on net tangible assets (%): 0.285670469386589
Capex to operating income (%): 81.08128827903177
Buffett classification: The Gruesome
Stock price: 5.623264311814861
P/E ratio: 21.2519275188416
Shares outstanding: 29097837
Book value: 111850146.16321559
P/B ratio: 1.462893290406067
Market cap (USD): 163624828.353106
Debt to equity: 0.17717404431303108
Current ratio: 1.62236500664307
Quick ratio: 0.487795407927682
Effective tax rate (%): 24.59515848315203
Interest coverage ratio: 9.479611461186002
COGS to revenue (%): 77.77898514317405
R&D to revenue (%): 0.49666116174812713
SG&A to revenue (%): 2.3222588437846103
Free cash flow (dilution-adjusted): -11947783.191230208
Buyback yield (%): 0
Retained earnings: 99665968.3313033
Inventory turnover: 1.622246163983295
Receivables turnover: 6.066956202378847
Capitalized R&D asset: 1763580.2049683866
ROCI (R&D-adjusted, %): 11.579123848323416
Rosenberg metric: -1.3320395071345146
FCF margin (%): -5.4576977556023145
Revenue growth (%): 10.799265834776039
Rule of 40 score: 5.341568079173724
Financial ratios for INSECTICID.NS — annual report dated 2024-03-31
Total revenue: 234606535.55582204
Gross profit: 57240928.168845184
Operating income: 16012855.25842427
Net income: 12240616.380861014
Capital expenditures: 5237606.427629212
Operating cash flow: 22422232.881640483
Depreciation & amortization: 3508058.5202062596
Net tangible assets: 119699172.56265739
Owner earnings: 10511068.473438062
Return on net tangible assets (%): 8.781237370655983
Capex to operating income (%): 32.7087601998634
Buffett classification: The Good
Stock price: 5.80158349328215
P/E ratio: 13.791260634012298
Shares outstanding: 29097837
Book value: 121323504.01726827
P/B ratio: 1.391433030201526
Market cap (USD): 168813530.8294146
Debt to equity: 0.08629826907077841
Current ratio: 1.8866792816594666
Quick ratio: 0.6703993427067518
Effective tax rate (%): 22.605223670672338
Interest coverage ratio: 14.516943348227391
COGS to revenue (%): 75.60130708497448
R&D to revenue (%): 0.4789295188945278
SG&A to revenue (%): 2.510074837561278
Free cash flow (dilution-adjusted): 16541899.508334333
Buyback yield (%): 0
Retained earnings: 109299856.09785345
Inventory turnover: 1.8319089779965587
Receivables turnover: 6.5945183878824905
Capitalized R&D asset: 2185179.1509201867
ROCI (R&D-adjusted, %): 12.476375465284722
Rosenberg metric: 7.905597968545222
FCF margin (%): 7.050911633447813
Revenue growth (%): 7.167291376067101
Rule of 40 score: 14.218203009514912
Financial ratios for INSECTICID.NS — quarterly report dated 2024-09-30
Capital expenditures: 0
Net tangible assets: 131925418.06020068
Buffett classification: The Gruesome
Stock price: 10.475752508361204
Shares outstanding: 29097837
Book value: 133571189.67988533
P/B ratio: 2.2820919666221924
Market cap (USD): 304821738.94063544
Debt to equity: 0.05897422598362811
Current ratio: 2.058914455503352
Quick ratio: 1.0850892612800833
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for INSECTICID.NS — quarterly report dated 2024-12-31
Total revenue: 41695384.07739829
Gross profit: 15058491.665695302
Operating income: 2717263.0842755563
Net income: 2024128.6863270777
Capital expenditures: 0
Depreciation & amortization: 883681.0817111551
Owner earnings: 2907809.768038233
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 7.822240354353655
P/E ratio: 28.11212996773683
Shares outstanding: 29097837
Market cap (USD): 227610274.80580488
Effective tax rate (%): 22.065740341806695
Interest coverage ratio: 16.578763957044305
COGS to revenue (%): 63.88451144197994
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for INSECTICID.NS — annual report dated 2025-03-31
Total revenue: 233146457.79752162
Gross profit: 71843254.6177227
Operating income: 22913514.145429038
Net income: 16602595.27706336
Capital expenditures: 4053109.6563011454
Operating cash flow: 10925520.224456394
Depreciation & amortization: 3408159.9251812017
Net tangible assets: 125201636.66121112
Owner earnings: 15957645.545943417
Return on net tangible assets (%): 12.745556664825353
Capex to operating income (%): 17.68873002445891
Buffett classification: The Great
Stock price: 6.872330493639865
P/E ratio: 12.044499620509491
Shares outstanding: 29097837
Book value: 126793757.30652325
P/B ratio: 1.5771277447882235
Market cap (USD): 199969952.51406232
Debt to equity: 0.09650036723425857
Current ratio: 1.8328847588424437
Quick ratio: 0.6930192926045016
Effective tax rate (%): 26.327207533975834
Interest coverage ratio: 40.222080853683565
COGS to revenue (%): 69.1853544349725
R&D to revenue (%): 0.5009339454940063
SG&A to revenue (%): 3.6210369492624808
Free cash flow (dilution-adjusted): 6566273.088613514
Buyback yield (%): 3.6175764624223823
Retained earnings: 122333960.72013092
Inventory turnover: 1.5568911274461903
Receivables turnover: 5.175835449558999
Capitalized R&D asset: 2279521.352278458
ROCI (R&D-adjusted, %): 17.222242141387873
Rosenberg metric: 12.996019110237217
FCF margin (%): 2.8163726571887526
Revenue growth (%): -0.6223516982769707
Rule of 40 score: 2.194020958911782
Financial ratios for INSECTICID.NS — quarterly report dated 2025-03-31
Total revenue: 41959375.730652325
Gross profit: 15356324.526537292
Operating income: 2490589.198036006
Net income: 1623930.3249941547
Capital expenditures: 0
Depreciation & amortization: 838251.110591536
Net tangible assets: 125201636.66121112
Owner earnings: 2462181.4355856907
Return on net tangible assets (%): 1.9665728829473859
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 6.872330493639865
P/E ratio: 30.784872576780984
Shares outstanding: 29097837
Book value: 126793757.30652325
P/B ratio: 1.5771277447882235
Market cap (USD): 199969952.51406232
Debt to equity: 0.09650036723425857
Current ratio: 1.8328847588424437
Quick ratio: 0.6930192926045016
Effective tax rate (%): 36.9254380587832
Interest coverage ratio: 9.951188752393852
COGS to revenue (%): 63.401923267130186
Buyback yield (%): 0
Retained earnings: 122333960.72013092
Inventory turnover: 0.25677143147936227
Receivables turnover: 0.9314952772590844
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 1.9010916564523164
Revenue growth (%): 0.6331435939383357
Rule of 40 score: 0.6331435939383357
Financial ratios for INSECTICID.NS — quarterly report dated 2025-06-30
Total revenue: 80872115.60964194
Gross profit: 23595892.815352213
Operating income: 9041926.047273578
Net income: 6799134.0978235435
Capital expenditures: 0
Depreciation & amortization: 855698.572431547
Owner earnings: 7654832.67025509
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 11.288790077229114
P/E ratio: 31.441878231091682
Shares outstanding: 29097837
Market cap (USD): 328479373.5944302
Effective tax rate (%): 24.980278489674447
Interest coverage ratio: 20.757615644979314
COGS to revenue (%): 70.823203229595
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): 92.73908203205924
Rule of 40 score: 92.73908203205924
Financial ratios for INSECTICID.NS — quarterly report dated 2025-09-30
Total revenue: 71894126.26832017
Gross profit: 24771014.656144306
Operating income: 9035839.909808343
Net income: 6663754.227733934
Capital expenditures: 0
Depreciation & amortization: 1051848.92897407
Net tangible assets: 133548162.34498309
Owner earnings: 7715603.156708004
Return on net tangible assets (%): 5.777393729145425
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 8.415107102593009
P/E ratio: 14.310219649910978
Shares outstanding: 29097837
Book value: 135642074.40811723
P/B ratio: 1.8052025219848775
Market cap (USD): 244861414.80879363
Debt to equity: 0.20483429597691122
Current ratio: 1.9747005290361732
Quick ratio: 0.9908882558993518
Effective tax rate (%): 25.044796219997945
Interest coverage ratio: 19.288113974923593
COGS to revenue (%): 65.54514820349165
Buyback yield (%): 0
Inventory turnover: 0.5617044836833276
Receivables turnover: 0.9922300576354616
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 6.461669044069578
Revenue growth (%): -11.101464668807761
Rule of 40 score: -11.101464668807761
Financial ratios for INSECTICID.NS — quarterly report dated 2025-12-31
Total revenue: 42878043.88994096
Gross profit: 13907296.424195167
Operating income: 2002584.3823103488
Net income: 1168341.316698229
Capital expenditures: 0
Depreciation & amortization: 1048490.5870558093
Owner earnings: 2216831.9037540383
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 7.957224016932161
P/E ratio: 14.243969784589584
Shares outstanding: 29097837
Market cap (USD): 231538007.41717726
Effective tax rate (%): 26.66927691468684
Interest coverage ratio: 3.8398052031270025
COGS to revenue (%): 67.56545970265736
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): -40.35946173138906
Rule of 40 score: -40.35946173138906
Financial ratios for KAMDHENU.NS — annual report dated 2022-03-31
Total revenue: 79070275.61651061
Gross profit: 20259949.887907162
Operating income: 6582170.6448635105
Net income: 3528234.2080970593
Capital expenditures: 1545496.5053408942
Operating cash flow: 5715613.873137281
Depreciation & amortization: 1227719.8997758143
Net tangible assets: 28761136.75326388
Owner earnings: 3210457.6025319793
Return on net tangible assets (%): 11.162485092553407
Capex to operating income (%): 23.48004311536566
Buffett classification: The Great
Stock price: 0.1587762099432942
P/E ratio: 12.685188042430084
Shares outstanding: 281883000
Book value: 28762231.306870632
P/B ratio: 1.5560793566372004
Market cap (USD): 44756314.3874456
Debt to equity: 0.4296010160290504
Current ratio: 1.7548221251887566
Quick ratio: 1.3433955667584458
Effective tax rate (%): 19.861964747795213
Interest coverage ratio: 13.478235039965435
COGS to revenue (%): 74.37728687557946
SG&A to revenue (%): 10.316000986674393
Free cash flow (dilution-adjusted): 4167018.330476065
Buyback yield (%): 0
Retained earnings: 18134155.347487804
Inventory turnover: 5.75930711443615
Receivables turnover: 3.0253363573751386
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 19.635980243086358
FCF margin (%): 5.270018724464839
Rule of 40 score: 5.270018724464839